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Time-averaged disease activity 
fits better joint destruction in 
rheumatoid arthritis
Hideaki Tsuji1, Koichiro Yano2, Moritoshi Furu3, Noriyuki Yamakawa1,4, Katsunori Ikari2, 
Motomu Hashimoto3, Hiromu Ito5, Takao Fujii3, Wataru Yamamoto6, Koichiro Ohmura1, Atsuo 
Taniguchi2, Shigeki Momohara2, Fumihiko Matsuda7, Cornelia F. Allaart8, Hisashi Yamanaka2, 
Tsuneyo Mimori1 & Chikashi Terao7,9,10,11,12
Disease activity of rheumatoid arthritis (RA), evaluated as Disease Activity Score (DAS), is associated 
with joint destruction. Since joint destruction reflects the history of disease activities, we hypothesized 
that time-averaged disease activity would better correlate with joint destruction than one-time disease 
activity. We recruited RA patients in IORRA (n = 557) and KURAMA (n = 204) cohorts, and calculated 
time-averaged DAS28 to model a modified Sharp/van der Heijde score (SHS). We evaluated the fitting 
of the model using time-averaged DAS28 among 1000 models in which we randomly picked up one-
time DAS28. We also used clinical disease activity index (CDAI) or data in the BeSt study (European 
population). After conditioning on autoantibody and disease duration, time-averaged DAS28 showed 
significant improvement of model fitting compared with one-time DAS28 in both cohorts (p = 0.001 and 
0.034, respectively). Time-averaged CDAI also showed a better fit. Integration of multiple DAS fit SHS 
better in the BeSt study. A good fit of time-averaged DAS could be observed using five to six time points 
of DAS. In conclusion, time-averaged disease activity fits the joint destruction model better than one-
time disease activity. Usage of time-averaged disease activity as a covariate would increase the power 
of studies to identify novel correlates of joint destruction.
Rheumatoid arthritis (RA) is a systemic disease of chronic synovitis and leads to joint destruction1. Treatment 
with disease modified anti-rheumatic drugs (DMARDs) and biologics improve disease activities of RA, but even 
during the treatment, inflammatory joint damage such as erosions and joint space narrowing can be progressive 
and irreversible due to the remaining disease activity, and result in functional impairment2. Investigation of risk 
factors associated with joint destruction of RA is important for its prevention. Evaluation by conventional plain 
radiographs of hands and feet using modified Sharp/van der Heijde score (SHS) is a standard imaging technique 
for the assessment of joint damage in patients with RA3, 4.
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Previous studies proved that high disease activity, commonly evaluated by Disease Activity Score 28 (DAS28), 
presence of cyclic citrullinated peptides antibodies (CCP) and rheumatoid factor (RF), disease duration, and 
genetic components correlate with joint destruction in RA5–12. CCP is an antibody which recognizes citrullinated 
peptides including filaggrin13, vimentin14, fibrin15, a-enolase16 and so on. Presence of CCP and RF are closely 
associated with each other, and 50% of RA patients have both CCP and RF11. We previously showed that RF is 
correlated with joint destruction independently of CCP, as CCP-negative RF-positive RA showed more joint 
destruction than CCP-negative RF-negative subjects17.
Since the prolonged period of inflammation leads to joint destruction, the association between DAS and SHS 
is reasonable. Most previous studies used one-time DAS28 as well as disease duration as independent variables for 
the assessment of the correlates of joint destruction18, 19. However, there remained a question whether one-time 
DAS is the best correlate for the assessment, since radiographic changes were considered to reflect the cumulative 
history of the disease activities, which changes over the disease period as well as the treatment course of RA.
On this point, the mathematical assessment of radiographic progression over time had been argued in previ-
ous studies. Some studies used not one-time DAS28 but time-integrated values of disease activities calculated as 
the area under the curve (AUC DAS) or generalized estimating equations (GEE), and the results correlated with 
radiographic progression in the cohorts of RA patients8, 18–20. All these observations suggest the appropriation of 
a linear model for radiographic progression based on the curve fitting of longitudinal data. However, to the best 
of our knowledge, there are no analyses to compare time-integrated values of DAS with one-time DAS to show 
superiority of time-integrated values. Furthermore, there is no information about how many DAS are necessary 
to get the better fit on joint destruction.
Here, we calculated time-averaged disease activity by using the available consecutive disease activity data and 
evaluated the superiority of time-averaged disease activity to one-time disease activity to fit the model for the 
assessment of joint destruction.
Results
We hypothesized that product of time-averaged disease activity and disease duration could well approximate 
cumulative disease activity (Fig. 1A) especially when patients started to come to the hospital soon after RA onset 
and received periodical follow-up (Fig. 1B). In such cases, time-averaged disease activity might fit joint destruc-
tion in RA very well. We also assumed that even when patients started to be followed-up in hospital several 
years after RA onset and/or they did not have so many time points of evaluation of disease activity (Fig. 1C), 
time-averaged disease activity using multiple time points would better correlate with joint destruction than 
one-time.
We used data from two different cohorts in Japan, the IORRA cohort (1st set, n = 557) and the KURAMA 
cohort (2nd set, n = 204), for evaluation of this hypothesis. Detailed characteristics of the two sets are shown in 
Figure 1. A new model to fit joint destruction in RA. (A) Schematic image of calculation of time-averaged 
DAS. We performed integration of DAS from the first visit to the hospitals to the time for the assessment of SHS, 
and divided the value by the time. (B) Schematic image of ideal cases who start to come to hospital soon after 
developing RA and are periodically followed-up. (C) Schematic image of cases who start to be followed-up later 
after development of RA.
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Table 1. Since the IORRA cohort had joint X-rays around five years after disease onset with periodical disease 
activity data, this cohort is similar to the model in Fig. 1B. Since the KURAMA cohort had joint X-rays with vari-
able disease duration and data of many time points of disease activity, this serves to address the model in Fig. 1C.
We calculated time-averaged DAS28 in each patient based on the methods illustrated in materials and meth-
ods and Fig. 1A. Mean and standard deviation of the time-averaged DAS28 seemed comparable to those in 
one-time DAS28 (Table 1), indicating difference observed between one-time and time-averaged DAS28 could 
not be explained by difference in score of DAS28 itself.
We first performed linear regression analysis with time-averaged DAS28 as an independent variable using RF 
and disease duration as covariates in the 1st set. We obtained R squared value (R2) of the model and compared 
it with those of the 1000 models using one-time DAS28 (for details, see Materials and Methods). As a result, we 
found superiority of the time-averaged DAS28 over the one-time DAS28 (p = 0.001, Fig. 2A and Supplementary 
Table 1).
Next, we analyzed data in the 2nd set in which dense data of disease activity were available for a short period 
of time in spite of long disease duration. As a result, the 204 samples revealed better fit in the model with 
time-averaged DAS28 than those with one-time DAS28. (p = 0.034, Supplementary Figure 1 and Supplementary 
Table 2) When we extracted hand SHS data and conducted the same analysis, we obtained comparable results of 
superiority of time-averaged DAS28 to one-time DAS28 (p = 0.054, Fig. 2B, and Supplementary Table 1).
Next, we used CDAI as an independent variable instead of DAS28 to confirm that our model was robust. 
Time-averaged CDAI tended to fit better than one-time CDAI in both sets 1 and 2 (Supplementary Tables 1 and 2). 
We further confirmed that the model by using time-averaged DAS28 consistently tended to fit better than 
one-time DAS28 where we used log-transformed SHS as alternative dependent variables or used DAS28 (CRP) 
or log-transformed disease duration as alternative independent variables (Supplementary Tables 1 and 2).
When we used one-time DAS28 evaluated at the first visit or at the time nearest the time of joint X-rays 
instead of randomly selected one-time DAS28, the DAS28 did not show very good fit consistently across the 1st 
and 2nd sets (Fig. 2A and B and Supplementary Tables 1 and 2). Since the IORRA cohort evaluated disease activity 
every six months, the disease activities for some patients were evaluated at a date far from the date of joint X-rays. 
However, when we selected the 516 patients whose DAS 28 data were evaluated within six months before joint 
X-rays, the last DAS 28 again showed a poor fit (Supplementary Figure 2), indicating that disease activity at last 
visit before or the same time of X-ray does not fit joint destruction very well.
When we divided the cohorts according to the number of assessment of DAS28, linear model using 
time-averaged DAS28 tended to fit well in a subgroup with more time points of DAS28 (Fig. 3). While differ-
ence in the characteristics of the two cohorts seemed to result in slightly different tendencies among the quad-
rants, a substantially better fit was observed in both cohorts in the quadrant with more than six evaluations 
(Supplementary Figure 3).
Lastly, we analyzed data of the BeSt study to confirm that the current findings are observed in a European 
cohort with definitive treatment and stringent control of disease activity. The characteristics of the subjects are 
1st set (IORRA) 2nd set (KURAMA)
Number of subjects 557 204
Age, years 55.2 ± 12.4 61.7 ± 12.8
Female sex 85% 85%
Stage Na 2.53 ± 1.08
Disease duration, years 4.72 ± 1.01 8.08 ± 6.08
Observation time, days 910 ± 465 239 ± 103
Number of measurement, times 5.76 ± 2.53 (1–12) 6.13 ± 3.34 (2–19)
SHS(total) Na 73.8 ± 80.8
SHS(hand) 22.7 ± 23.4 50.2 ± 55.2
DAS28(ESR) 3.56 ± 1.31 3.22 ± 1.34
DAS28(CRP) Na 2.39 ± 1.06
CDAI 9.33 ± 8.12 9.02 ± 7.86
First DAS28(ESR) 4.23 ± 1.26 3.60 ± 1.46
First DAS28(CRP) Na 2.77 ± 1.18
First CDAI 13.29 ± 8.84 11.7 ± 9.32
Latest DAS28(ESR) 3.30 ± 1.20 3.05 ± 1.19
Latest DAS28(CRP) Na 2.10 ± 0.93
Latest CDAI 7.64 ± 6.68 7.13 ± 6.25
Time-averaged DAS28(ESR) 3.60 ± 1.05 3.18 ± 1.10
Time-averaged DAS28(CRP) Na 2.33 ± 0.81
Time-averaged CDAI 9.50 ± 6.35 8.47 ± 5.62
RF positive 87% 83%
CCP positive 85% 81%
Table 1. Baseline characteristics of patients for the assessment of time-averaged DAS28 in the Japanese cohorts.
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shown in Table 2. As a result, we found that time-averaged DAS44 showed a substantially better fit than one-time 
DAS44 across the different years evaluated (Fig. 4A). We observed this better fit even in the first year, indicating 
that five time points of DAS might be enough for the better fit. This seemed to be compatible with the results in 
the Japanese data. We also confirmed that DAS44 at the first point or at the time nearest to the X-ray evaluations 
did not show good fits (data not shown). The decrease of the number of subjects and low disease activity in the 
later follow-up years of the study seemed to explain the better p-values in the first and the third year than years 
after the five years (Fig. 4B).
Collectively, these results suggest that a model of joint destruction in patients with RA using time-averaged 
disease activity as an independent variable fits better than a model using one-time disease activity and has better 
power to identify unknown correlates of joint destruction.
Figure 2. Better fit of time-averaged disease activity on joint destruction than one-time disease activity in 
the Japanese subjects. Empirical p-values of time-averaged DAS28 are indicated for (A) the IORRA and (B) 
KURAMA cohorts. Bar charts indicate distribution of R2 of the 1000 one-time DAS28. The solid and broken 
arrows indicate the time-averaged DAS28 and the latest DAS28, respectively. The arrowheads indicate the first 
DAS28.
Figure 3. Good fit of time-averaged DAS28 was driven by subjects with more numbers of DAS28. The bar 
charts indicate −log10 empirical P-values of R2 of time-averaged DAS28 in each quadrant based on the number 
of time points of DAS28.
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Discussion
In this study, we showed the superiority of time-averaged disease activity to one-time disease activity to assess 
association with joint destruction using three independent cohorts. We also compared time-averaged disease 
activity with the first or latest disease activity, since these values were representatives of disease activity frequently 
used in the previous studies to fit joint destruction.
Although previous studies argued the mathematical assessment of joint destruction8, 18–22, there were no anal-
yses that compared time-integrated values with one-time disease activity.
While the two Japanese cohorts of SHS did not have inter-observer coefficients, high intra-observer coef-
ficients as well as the results from our previous studies using the data support the accuracy of the SHS6, 23. We 
observed the better fit using time-averaged disease activity in the two Japanese cohorts with different character-
istics of observation period and density of disease activity data. We also confirmed the findings using a European 
cohort with definitive treatment and stringent control of disease activity. Among the three cohorts, the BeSt study 
is the most similar to the model shown in Fig. 1B. Thus, we can generalize our model in a wide variety of RA data 
regardless of observation period, frequencies of disease activity data and populations. Since we showed better fit 
using time-averaged CDAI, we can apply this model into data sets or cohorts without consecutive laboratory data. 
Comparable results of SHS between data of only hands and that of hands and feet suggest that we can apply this 
model even when SHS data of only hands are available.
Since the IORRA cohort has data of SHS in patients with RA with disease duration around 5 years24, they 
showed shorter disease duration with small variance, smaller SHS and younger age. These differences in cohorts 
could also explain the difference in R2 between the two cohorts in the Japanese.
BeSt study
Number of subjects at registry 508




ΔSHS (in the first year) 2.09 ± 7.91
First DAS44 4.45 ± 0.87
Latest DAS44 (in the first year) 2.14 ± 1.05
Time-averaged DAS44 (in the first year) 2.77 ± 0.92
Table 2. Characteristics of subjects in the BeSt study.
Figure 4. Better fit of time-averaged disease activity on joint destruction than one-time disease activity 
in the BeSt study. (A) Empirical p-values of time-averaged DAS44 from the registry to the study years 
are indicated. The horizontal line indicates p-value of 0.05. (B) Bar charts indicate the number of the 
subjects in the study years. Dot plots and error bars indicate mean and standard deviation of DAS44 in the 
study years. IORRA = Institute of Rheumatology, Rheumatoid Arthritis; KURAMA = Kyoto University 
Rheumatoid Arthritis Management Alliance; na = not applicable; SHS = modified Sharp/van der Heijde score; 
DAS28 = disease activity score 28; CDAI = Clinical Disease Activity Index; RF = rheumatoid factor, and 
CCP = anti-cyclic citrullinated peptide antibody. The data were expressed with mean ± standard deviation for 
variables.
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We used RF as a covariate since we previously showed high co-occurrence of RF and CCP and a 
joint-destructive association of RF which was independent of CCP. When we used CCP as a covariate or CCP and 
RF as covariates, we obtained similar results (data not shown).
We assumed that treatment effects were substantially reflected in disease activity. In addition, the validation 
using the BeSt study supports the current findings.
We also showed that the better fit on joint destruction could be obtained using disease activity from five to 
six time points. Since the BeSt study had a limited number of subjects with less than four time points of DAS, we 
could not subdivide the patients as in the Japanese subjects.
It is interesting that the better fit did not appear to be completely dependent on number of time-points in a 
definitive meaning. The better fit seemed to be obtained using five to six time-points and no further improve-
ments were obtained in the subjects with more time-points in the three cohorts.
The results in the BeSt study also suggest that better fit might be brought about by high to moderate disease 
activity during disease course since we did not find improvement after the third year. This seems reasonable since 
high disease activity leads to joint destruction and long period of remission would make the average of disease 
activity difficult to properly reflect high disease activity in a short period.
Our model is an integration of disease activity from the first visit to the time of radiographic assessment 
approximating average of disease activity during disease course of the patients. This model is intuitive and it 
should be noted that while time-averaged disease activity seemed comparable to one-time disease activity as a 
whole in the Japanese cohorts, we obtained significant results, indicating the importance of using appropriate 
disease activity in each patient to model SHS.
Our model has limitations as well: we cannot evaluate the disease activity between onset of RA and the first 
visit to hospitals since there are no measures to obtain the patient’s DAS of that period. Time-averaged disease 
activity using a limited number of time points may not very accurately approximate disease activity over the dis-
ease course. In addition, we could not capture variation of DAS between the consecutive visits if DAS fluctuated 
during the two visits. As we observed in the BeSt study, long term of low disease activity or remission would 
confound fit of the model since time-averaged disease activity cannot fully project short period of high disease 
activity and slight difference in disease activity in remission between patients do not seem to well correlate with 
difference in joint destruction. We excluded patients whose disease durations were over 20 years because SHS do 
not linearly correlate with DAS in long disease duration25. Weighing DAS based on disease duration would lead 
to better fit of this model. The time-averaged DAS is cumulative disease activity over an observation period esti-
mated by joint swellings, tendencies, and CRP (or ESR). Thus, disease activity not evaluated by these components 
can be missed and integration of these factors would improve the fitting. In addition, usage of imaging modalities 
including micro CT which may evaluate joint destruction more accurately than X-rays would lead to better fitting 
of this model.
In spite of these limitations, the highly significant results in the current study indicate the importance of using 
disease activity by integrating multiple time points to fit SHS. It would be interesting to perform linear regression 
analysis using this model to find yet-to-be-identified correlates of joint destruction in RA. In addition, it would 
be interesting to use the current model to show associations between genetic components or autoantibodies and 
joint destruction which are independent of disease activity.
Intensive treatment such as biological DMARDs can be used in the patient from the early stages of RA and a 
subset of patients show repair of joint destruction after such treatment. Since we do not have enough number of 
sequential SHS data in patients treated with biological DMARDs, future studies would clarify whether healing 
effect of biological DMARDs can be appropriately modeled by our model with some modifications.
In summary, we showed that integration of time-averaged disease activity in the linear regression model fits 
SHS better than one-time disease activity. Time-averaged disease activity is a simple mathematical model and its 
use as a covariate would increase the power of studies to identify novel correlates of SHS.
Materials and Methods
Japanese Patients. We recruited 557 patients in the Institute Of Rheumatology, Rheumatoid Arthritis 
(IORRA) cohort26 and 204 patients in the Kyoto University Rheumatoid Arthritis Management Alliance 
(KURAMA) cohort6, whose data of SHS, DAS28, CDAI (Clinical Disease Activity Index), RF, CCP, and disease 
duration were available. DAS28/CDAI at regular six-month intervals was available in the IORRA cohort since this 
cohort systematically collects clinical information every six months.
DAS28/CDAI was available for every hospital visit in the KURAMA cohort since this cohort aims to deeply 
phenotype registrants to get insight of the disease. Since the KURAMA cohort was launched in 2011, the period 
of which DAS28 or CDAI are available is shorter than the disease duration. As SHS may not linearly reflect dis-
ease duration among patients with long RA history25, we did not recruit patients with more than 20 years duration 
of RA in the KURAMA cohort.
Written informed consent to use clinical data was obtained from all the participants. This study was conducted 
in accordance with the Declaration of Helsinki and its amendments and was approved by the Ethics Committee 
in Tokyo Women’s Medical University Hospital and Kyoto University Hospital.
SHS score. X-rays of the patients’ joints were assessed by the SHS method3, 4. The X-rays in the IORRA cohort 
were taken between 4 to 6 years after onset of RA, while the timings of X-rays in the KURAMA cohort were var-
iable. The X-rays were blindly evaluated by trained rheumatologists (KY and MF for the IORRA and KURAMA, 
respectively) with intra-observer agreement of 0.93 and 0.95, respectively (details omitted)6. Since foot X-rays 
were not available for patients in the IORRA cohort, the scores for the hand X-rays were used for analyses and 
shown in the main figures. Scores for hand and foot were analyzed only in the KURAMA cohort and shown in 
Supplementary materials.
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Clinical laboratory variables as covariates. The baseline characteristics of the RA patients were obtained 
as covariates from the database of the IORRA and KURAMA cohorts, including disease duration, RF (by latex 
turbidimetric immunoassay, positive at >20 IU/mL), and CCP (Medical and Biological Laboratories, by chemi-
luminescent enzyme immunoassay, positive at ≥4.5 U/mL). These variables were decided based on the previous 
studies5–12.
The BeSt study. To validate the findings in the two Japanese cohorts, we used the data in the BeSt study, in 
which 507 subjects with early RA were registered to be treated by finely-defined treatment regimen to control 
disease activity27. The SHS inter-observer correlation coefficient was 0.96 in this study, as previously described27. 
Patients visited medical institutions every 3 months and their disease activities were evaluated as DAS44 on a reg-
ular basis. X-rays for hands and feet were taken annually. The data including SHS, DAS44 and basic clinical infor-
mation was provided by one of the authors (CAF). This study was approved by the medical ethics committees and 
boards of all participating hospitals. Written and oral information about the trial, including an explanation about 
using the data (under code) for research on RA in future studies was obtained by the patients’ rheumatologists.
Calculation of time-averaged disease activity. We calculated time-averaged DAS28 as follows to model 
SHS together with the other covariates. Time-averaged DAS is the cumulative effect of disease activity estimated 
by joint swellings, tendencies, and CRP (or ESR). The following equation was used to approximate average DAS 















k k k k n
0 2
1 1 1
where n indicates the number of DAS measurement from the first visit to the time of the radiographical assess-
ment, tk indicates the time of the k-th measurement of DAS from the first visit, and DAS(tk) indicates the DAS 
score of k-th measurement. We also applied the same statistical framework to CDAI in the Japanese cohorts and 
to DAS44 in the BeSt study.
Calculation of random disease activity. We randomly picked up disease activity 1000 times in each 
patient from multiple disease activities of different visits during the observation periods, and constructed 1000 
sets of one-time disease activity in the RA patients.
Statistical Analysis. In the Japanese cohorts, linear regression analysis was performed with SHS as a 
dependent variable and positivity of autoantibodies (RF), disease duration, and one-time or time-averaged dis-
ease activity (DAS28 or CDAI) as independent variables. We used DAS28 (ESR) for the analysis and confirmed 
the results by using DAS28 (CRP) which were available only in the KURAMA cohort. We also performed linear 
regression analysis with log-transformed SHS score (log10(SHS + 1)) and log-transformed disease duration as a 
dependent variable and an independent variable, respectively.
In the BeSt study, the difference in SHS (ΔSHS) between the evaluation year and the time of registration was 
calculated and used as the dependent variable. Since we found a part of the samples showed extreme values of 
ΔSHS resulting in a deviated distribution, we log-transformed ΔSHS (log10(ΔSHS + 1)). We used RF positivity, 
indicator variables of treatment arms and one-time or time-averaged DAS44 as independent variables.
We performed linear regression analysis with use of each of the 1000 one-time disease activity or 
time-averaged disease activity. We evaluated fitting the model of time-averaged disease activity by comparing R2 
of the linear regression model with those of the 1000 models using one-time disease activity. We also evaluated 
fitness of the model with use of disease activity at the first visit and the latest visit before or at the same time of 
joint X-rays.
We also divided the subjects into four groups based on the number of available time points of disease activity 
in the Japanese cohorts to analyze time-points-dependency of model fitting.
A p-value less than 0.05 was set as the cut-off level for statistical significance. Statistical analyses were per-
formed using R software or JMP Pro 11 software.
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